

FITC-equivalent Biotinylated Human CD20 Protein-VLP

Cat. No. CD2-HM0P10B

Description

Source	Recombinant FITC-equivalent Biotinylated Human CD20 Protein-VLP is expressed from HEK293. It contains Met1-Pro297.
Accession	P11836-1
Molecular Weight	The target protein has a predicted MW of 34.3 kDa.
Wavelength	Excitation Wavelength: 490 nm Emission Wavelength: 520 nm
Endotoxin	Less than 1EU per µg by the LAL method.

Formulation and Storage

Formulation	Supplied as 0.22 µm filtered solution in PBS, 150mM L-Arginine (pH 7.4).
Storage	Valid for 12 months from date of receipt when stored at -80°C. Recommend to aliquot the protein into smaller quantities for optimal storage. Please minimize freeze-thaw cycles.

Background


B-lymphocyte antigen CD20 or CD20 is an activated-glycosylated phosphoprotein expressed on the surface of all B-cells beginning at the pro-B phase (CD45R , CD117) and progressively increasing in concentration until maturity. CD20 is the target of the monoclonal antibodies rituximab, ocrelizumab, obinutuzumab, ofatumumab, ibritumomab tiuxetan, tositumomab, and ublituximab, which are all active agents in the treatment of all B cell lymphomas, leukemias, and B cell-mediated autoimmune diseases.

Assay Data

ELISA Data

FITC-equivalent Biotinylated Human CD20 VLP ELISA

0.5µg FITC-equivalent Biotinylated Human CD20 VLP Per Well



Immobilized FITC-equivalent Biotinylated Human CD20 VLP at 5µg/ml (100µl/well) on the streptavidin precoated plate (5µg/ml). Dose response curve for Rituximab with the EC50 of 0.24µg/ml determined by ELISA (QC Test).